Dossier assessment

Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

Status
Status: Commission completed
Project no.
A21-126
Last updated

Report documents

  1. Extract of dossier assessment

    Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

    published on
    Document type
    PDF document, 687 kB, EN, not accessible
  2. Dossier assessment

    Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

    published on
    Document type
    PDF document, 4 MB, DE, not accessible

Dossier assessment

Indication:

Adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant

Result of dossier assessment:

Hint of considerable added benefit

Press releases

Daratumumab in multiple myeloma: reassessment shows hint of considerable added benefit

Because of new scientific findings, the manufacturer requested a new early benefit assessment. The latest data cut-off of the MAIA study now shows an advantage in overall survival.

Additional information

Federal Joint Committee (G-BA)

2022-03-18 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A21-126
Commission
Commission awarded on 01.10.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-01-03.

Connected Projects

  1. Dossier assessment

    Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-15
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-14
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-66
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-40
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V

    Project no.
    G16-02
    Last updated

    Status: Commission completed

  6. Addendum

    Daratumumab (multiple myeloma) - Addendum to Commission A21-126

    Project no.
    A22-27
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-109
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-127
    Last updated

    Status: Commission completed

  9. Dossier assessment

    Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-40
    Last updated

    Status: Commission completed

  10. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    Project no.
    A22-40
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form